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INTRODUCTION
According to the National Surgical Adjuvant Breast and Bowel 
Project P1 (NSABP-P1) study [1], tamoxifen can prevent 49% 
of invasive breast cancer in patients who have a 5-year risk of 
1.67% or more. Based on this study, the U.S. Food and Drug 
Administration (FDA) approved tamoxifen as a preventive 
agent for breast cancer. However, many doctors and patients 
are reluctant to take tamoxifen for prevention because of its 
life threatening side effects. Tamoxifen increases the risk of 
endometrial cancer by 2.53 times, the risk of ischemic stroke by 
1.59 times and the risk of pulmonary embolism by 3.01 times 
[1]. Tamoxifen also has the beneficial effects of preventing     
osteoporosis, and decreasing the risk of hip fracture by 0.55 
times [1]. 
Gail et al. [2] proposed a risk-benefit index to weigh the risks 
and benefits of tamoxifen chemoprevention. They showed that 
tamoxifen was most beneficial for younger women with an   
elevated risk of breast cancer. They also showed that tamoxifen 
was not suitable for low-risk older patients.
Korean women have different breast cancer probabilities 
compared to Western counties [3]. It is not certain that tamox-
ifen is beneficial to Korean women as a chemopreventive agent. 
Therefore, we estimated the risks and benefits of tamoxifen 
using a Korean database in order to evaluate the feasibility of 
using tamoxifen for chemoprevention in Korean women.
METHODS
Data sources
To calculate a risk-benefit index of preventive tamoxifen, we 
used different data sources. For the preventive effects of tamox-
ifen, we could not know the exact chemopreventive effects of 
tamoxifen for Korean women because there were no prospec-
tive randomized controlled studies about tamoxifen chemo-
prevention in Korea. Therefore, we assumed that the effect of 
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tamoxifen on Korean women was the same as on U.S. women. 
We used the relative risks of breast cancer, hip fracture, endo-
metrial cancer and ischemic stroke from the NSABP-P1 study 
[1]. We summarized assumed relative risks with 95% confi-
dence intervals in Table 1.
The incidence rates of hip fracture for Korean women were 
obtained from the study [4] that used the Korean National 
Health Insurance database. We re-calculated the incidence 
rate of female hip fractures according to 10-year age intervals 
[4]. There was no data under the age of 50, but a hip fracture 
at a young age is a rare event. So we assumed that the incidence 
is zero for those under age 50. 
The incidence rates of stroke were obtained from another 
study [5] that also used the Korean National Health Insurance 
database. That study showed the 10-year probability of stroke 
per hundred individuals calculated for five-year age intervals. 
We re-calculated the incidence rate of female stroke according 
to the 10 year age intervals. Among those with cerebrovascular 
stroke, tamoxifen increases the incidence of ischemic stroke, 
but not hemorrhagic stroke. In the same study [5], the propor-
tion of patients with an ischemic stroke was 58.9% of all females 
who had strokes. So we multiplied 0.589 by the incidence of 
strokes. 
For the incidence rates of endometrial cancer, we used age-
specific endometrial cancer incidence rates from the Korea 
Central Cancer Registry data [6]. 
The overall mortality rates and cause-specific mortality rates 
for patients with endometrial cancer and ischemic stroke were 
obtained from statistics on cause-specific death from the Korea 
National Statistical Office [7]. We searched the web-based   
Korea National Statistical Office’s database by the International 
Classification of Disease (ICD)-10 diagnostic codes I63 for 
ischemic stroke and C54, C55 for endometrial cancer. The mor-
tality rates for hip fracture were obtained from the hip fracture 
study [4]. The incidence rates and the mortality rates of hip 
fracture, endometrial cancer and ischemic stroke are summa-
rized in Table 2.
Expected number of breast cancer prevented
To calculate the expected number of invasive breast cancer 
prevented over a 5-year period, we multiplied the estimated 
5-year risk of invasive breast cancer by the relative risk reduced 
by tamoxifen. For example, if the 5-year risk of invasive breast 
cancer is 1%, it means that 100 breast cancers will occur among 
10,000 people over a 5-year period. If they take a tamoxifen 
for prevention, 49 breast cancers will be prevented because the 
assumed relative risk of breast cancer is 0.51. The 5-year risk 
of invasive breast cancer was calculated by the Korean breast 
cancer risk assessment tool [3], a web-based breast cancer risk 
assessment tool for Korean women. In the tool, the risk factors 
for breast cancer (age, family history, body mass index, age of 
first delivery, breast feeding history and breast biopsy history) 
are entered, and breast cancer risk in the following 5 years and 
10 years, and up to ages 64 and 74 years are calculated. 
Expected number of non-breast cancer events with and 
without tamoxifen
To calculate the expected number of hip fractures, endome-
trial cancers and ischemic strokes, we used Equation 1 which 
is the same method as that of Gail et al. [2]. In equation 1, the 
hazard rate means the incidence rate multiplied by the relative 
risk in Table 1. In tamoxifen untreated people, the relative risk 
is one, so the hazard rate is the same as the incidence rate. Mor-
tality rates from other causes were calculated by subtraction of 
cause-specific mortality rates from overall mortality rates. In 
Table 1. Assumed relative risks from NSABP-P1 study
Type of event Relative risk 95% CI 
Breast cancer 0.51 0.39-0.66
Hip fracture 0.55 0.25-1.15
Endometrial cancer 2.53 1.35-4.97
Ischemic stroke 1.59 0.93-2.77
NSABP-P1=National Surgical Adjuvant Breast and Bowel Project P1; CI= 
confidence interval.
Table 2. Incidence and mortality rates per 1,000 women-years in Korea
                               Reference
Age group (yr)
35-39 40-49 50-59 60-69 70-79
Incidence rates
   Hip fracture Kang HY et al. [4] 0.00 0.00 0.12 0.66 2.45
   Endometrial cancer Korean Central Cancer Registry [6] 0.03 0.06 0.11 0.08 0.05
   Ischemic stroke Jee SH et al. [5] 0.22 0.79 2.38 5.23 7.63
Mortality rates
   Hip fracture Kang HY et al. [4] 0.00 0.00 0.01 0.06 0.32
   Endometrial cancer Korean Statistical Information Service [7] 0.00 0.01 0.02 0.03 0.07
   Ischemic stroke Korean Statistical Information Service [7] 0.00 0.01 0.07 0.43 2.33
   Overall mortality Korean Statistical Information Service [7] 0.75 1.35 2.95 8.09 28.45TamoxifenforBreastCancerChemoprevention 53
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Table 3, we summarized the calculated number of hip fractures, 
endometrial cancers and ischemic strokes in the tamoxifen 
untreated and treated groups. The differences between tamox-
ifen treated and untreated cases also summarized. We compared 
these results with the results of Gail et al. [2] for U.S. women.
(Equation 1)
Expected number of non-breast event over 5 years 
= hazard rate / (hazard rate + mortality rate from other 
     causes) × [1 – exp{-5 × (hazard rate + mortality rate 
     from other causes)}] 
Risk-benefit index
To estimate the risks and benefits of tamoxifen chemopre-
vention, we followed the methods of Gail et al. [2]. Life-threat-
ening events related to tamoxifen are invasive breast cancer, 
hip fracture, endometrial cancer and stroke. The benefits of 
tamoxifen are prevention of both invasive breast cancer and 
hip fracture. The risks of tamoxifen are endometrial cancer 
and stroke (Figure 1). To summarize the risks and benefits of 
tamoxifen in a single number, we defined the risk-benefit index 
as follows: 
(Equation 2)
Risk-benefit index 
= expected number of invasive breast cancer prevented
    + expected number of hip fracture prevented
    – expected number of endometrial cancer
    – expected number of stroke
As the study of Gail et al. [2] suggested, we assumed that the 
magnitude of each event of breast cancer, hip fracture, endo-
metrial cancer and stroke was the same. For example, one case 
of endometrial cancer that occurs is equivalent to one case of 
breast cancer prevented. If the risk-benefit index is negative, it 
shows that tamoxifen has more risk than benefit. For women 
with a previous history of hysterectomy, there is no risk of     
endometrial cancer. So we calculated this separately for women 
with a hysterectomy without adding the risk of endometrial 
cancer. We calculated the risk-benefit index for average 5-year 
risk of breast cancer according to the study of Kim et al. [3].
Sensitivity analysis
We assumed that the effect of tamoxifen on Koreans was 
the same as on the U.S. women and used the relative risks of 
breast cancer, hip fracture, endometrial cancer and ischemic 
stroke from NSABP-P1. But it was not certain that the effect of 
tamoxifen on Korean women was the same as for U.S. women. 
So we conducted sensitivity analyses in which we varied our 
assumptions regarding the relative risks of breast cancer, hip 
fracture, endometrial cancer and ischemic stroke. We calcu-
lated the 5-year risk of breast cancer for specific age groups 
when the risk-benefit index was zero, which meant that the 
risk and the benefit for tamoxifen was the same. In one-way 
sensitivity analysis, each parameter of relative risk of breast 
cancer, hip fracture, endometrial cancer and ischemic stroke 
was varied separately from the lower limit to the upper limit 
of the 95% confidence interval. Then, we conducted sensitivity 
analysis including all relative risks in the same way.
RESULTS
Expected number of non-breast cancer events without 
tamoxifen chemoprevention
The expected numbers of hip fractures, endometrial cancers 
and ischemic strokes were calculated using Equation 1. The 
expected numbers of hip fractures and ischemic strokes increased 
with age (Table 3). The expected number of endometrial cancers 
is highest in the sixth decade of life.
From the results of the study of Gail et al. [2], the expected 
numbers of hip fractures per 10,000 in tamoxifen untreated 
U.S. white women were 50 for women in their 50s, 116 for 
women in their 60s and 339 those in their 70s. For endome-
Table 3. Calculated numbers of non-breast cancer events expected in 
5 years among 10,000 tamoxifen untreated and treated Korean women
Age group
35-39 40-49 50-59 60-69 70-79
Tamoxifen untreated
   Hip fracture 0.0 0.0 5.8 32.5 113.7
   Endometrial cancer 1.3 3.2 5.6 3.8 2.5
   Ischemic stroke 10.9 39.1 117.4 253.2 351.1
Tamoxifen treated
   Hip fracture 0.0 0.0 3.2 17.9 62.7
   Endometrial cancer 3.3 8.1 14.2 9.7 6.3
   Ischemic stroke 17.4 62.0 186.0 399.5 552.1
Difference between treated 
      and untreated
   Hip fracture 0.0  0.0  -2.6  -14.6  -51.0 
   Endometrial cancer 2.0  4.9  8.6  5.9  3.8 
   Ischemic stroke 6.4  23.0  68.6  146.3  201.1 
Figure 1. Weighing the life-threatening risks and benefits of tamoxifen 
chemoprevention for Korean women.
Benefits
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trial cancers, the expected numbers of the same U.S. white 
women were 10 for those in their 40s, 40 for those in their 50s, 
70 for their 60s and 75 for their 70s. For ischemic strokes, the 
expected numbers of the same U.S. white women were 22 for 
ages 40-49, 54 for 50-59, 156 for 60-69, and 342 for age 70 and 
over. Expected numbers of hip fractures and endometrial can-
cers were lower in Korean women than in U.S. white women, 
but the expected number of ischemic strokes was much higher 
in Korean women.
Expected number of non-breast cancer events with tamoxifen 
chemoprevention
The expected number of hip fractures was decreased by 
tamoxifen, but the expected numbers of endometrial cancers 
and ischemic strokes were increased by tamoxifen (Table 3). The 
number of ischemic strokes dramatically increased with age. 
This increase was exaggerated with tamoxifen treatment (Table 
3). The magnitude of endometrial cancer was smaller than that 
of hip fractures or ischemic strokes induced by tamoxifen.
Risk-benefit index of tamoxifen chemoprevention
The risk-benefit index was calculated using Equation 2. In 
Tables 4 and 5, the shaded area shows a positive risk-benefit 
index that has more benefits than risks. For the specific 5-year 
risk of breast cancer, the net benefit of tamoxifen was reduced 
according to increases with age because of the high risk of 
stroke in older women. So older Korean women had more 
risk than benefit from tamoxifen chemoprevention.
Comparing non-hysterectomy (Table 4) and hysterectomy 
(Table 5) women, there was little difference in the risk-benefit 
index because the incidence of endometrial cancer was low. 
The effect of endometrial cancer is smaller than effects of hip 
fracture or ischemic stroke induced by tamoxifen.
According to the study of Kim et al. [3], the average 5-year 
risk of breast cancer in Korea was 0.18% for age 35, 0.38% for 
age 45, and 0.28% for age 55. At that average risk of breast 
cancer, the risk-benefit index was 0.4, -9.3, and -61.0 for ages 
35, 45, and 55, respectively. Therefore, only women younger 
than age 40 had a positive risk-benefit index for average 5-year 
risk of breast cancer. 
Sensitivity analysis regarding the effects of tamoxifen
We calculated the 5-year risk of breast cancer at each specific 
age group when the risk-benefit index was zero, which meant 
that the risk and benefit from tamoxifen was the same. The 
numbers were 0.17% for women in their 30s, 0.57% in their 
40s, 1.52% in their 50s, 2.81% in their 60s, and 3.14% for women 
in their 70s. Sensitivity analysis regarding the 95% confidence 
interval of breast cancer relative risk as parameters, the point 
was converged as the age decreased. Sensitivity analyses regard-
Table 4. Without history of hysterectomy, risk-benefit indices for tamoxi-
fen chemoprevention by level of 5-year risk of breast cancer and age 
group among 10,000 Korean women
5-yr risk (%) 35-39 40-49 50-59 60-69 70-79
0.05 -6.0  -25.4  -72.1  -135.1  -151.5 
0.1 -3.5  -23.0  -69.7  -132.7  -149.0 
0.2 1.4  -18.1  -64.8  -127.8  -144.1 
0.3 6.3  -13.2  -59.9  -122.9  -139.2 
0.4 11.2  -8.3  -55.0  -118.0  -134.3 
0.5 16.1  -3.4  -50.1  -113.1  -129.4 
1.0 40.6  21.1  -25.6  -88.6  -104.9 
1.5 65.1  45.6  -1.1  -64.1  -80.4 
2.0 89.6  70.1  23.4  -39.6  -55.9 
2.5 114.1  94.6  47.9  -15.1  -31.4 
3.0 138.6  119.1  72.4  9.4  -6.9 
3.5 163.1  143.6  96.9  33.9  17.6 
Table 5. With history of hysterectomy, risk-benefit indices for tamoxifen 
chemoprevention by level of 5-year risk of breast cancer and age group 
among 10,000 Korean women
5-yr risk (%) 35-39 40-49 50-59 60-69 70-79
0.05 -4.0  -20.5  -63.5  -129.2  -147.6 
0.1 -1.5  -18.1  -61.1  -126.8  -145.2 
0.2 3.4  -13.2  -56.2  -121.9  -140.3 
0.3 8.3  -8.3  -51.3  -117.0  -135.4 
0.4 13.2  -3.4  -46.4  -112.1  -130.5 
0.5 18.1  1.5  -41.5  -107.2  -125.6 
1.0 42.6  26.0  -17.0  -82.7  -101.1 
1.5 67.1  50.5  7.5  -58.2  -76.6 
2.0 91.6  75.0  32.0  -33.7  -52.1 
2.5 116.1  99.5  56.5  -9.2  -27.6 
3.0 140.6  124.0  81.0  15.3  -3.1 
3.5 165.1  148.5  105.5  39.8  21.4 
Figure 2. Sensitivity analysis regarding the 95% confidence interval of 
relative risk as parameters in the women with and without hysterectomy.
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ing relative risk of hip fracture, endometrial cancer and isch-
emic stroke showed similar results. Sensitivity analysis that     
included all relative risks in the same way, also showed similar 
results (Figure 2). It showed that the result of this study regard-
ing women younger than age 40 is robust.
DISCUSSION
Since 1999, tamoxifen has been recommended in the U.S. to 
prevent breast cancer. Of 10 million U.S. women, it was esti-
mated that 2.4 million would benefit from taking tamoxifen 
for chemoprevention [8]. However, only 0.2% of U.S. women 
took tamoxifen for chemoprevention in 2000, and only 0.08% 
of U.S. women took tamoxifen for chemoprevention in 2005 
[9]. The decline was due to life-threatening effects of tamoxifen: 
endometrial cancer, stroke and pulmonary embolism. There-
fore, Gail et al. [2] proposed a risk-benefit index of tamoxifen 
chemoprevention. According to that study, women younger 
than 50 years old had more benefits than risks. If women had 
a hysterectomy, there was no risk of endometrial cancer. There-
fore, women younger than 60 years old had more benefits than 
risks.
In Korea, tamoxifen is popular as a therapeutic agent but 
not as a preventive agent. The incidence of breast cancer in 
Korean women is much lower than in U.S. women. Therefore, 
the benefit of tamoxifen for prevention would also be low. 
This study showed that only Korean women younger than age 
40 had a positive risk-benefit index for average 5-year risk of 
breast cancer. 
In this study, we used the relative risks of NSABP-P1 for 
breast cancer, hip fracture, endometrial cancer and stroke,     
assuming that the effect of tamoxifen prevention for Korean 
women was the same as for U.S. women. This point is the most 
important drawback in this study. In the NSABP-P1 study, Asian 
Americans were rarely enrolled and there was no evidence of 
tamoxifen chemoprevention in Korea until now. So we agree 
on the necessity of doing a tamoxifen chemopreventive trial 
for Korean women. This study will be useful to suggest enroll-
ment criteria for a future tamoxifen prevention trial.
Although there is no evidence of tamoxifen preventing breast 
cancer in Korean women, some high-risk patients are taking 
tamoxifen for preventive purpose. So a presumptive guideline 
of preventive tamoxifen is thought to be needed. This study 
will be useful to guide the use of preventive tamoxifen.
The relative risk of Korean women can be calculated by large 
sized case-control study. It is possible that using tamoxifen for 
prevention in Korean women will have different effects than 
this study. If the relative risks of Korean women are different 
from those of U.S. women, the results of this study will be wrong. 
Therefore, we did sensitivity analyses to overcome the uncer-
tainty due to the assumed relative risks. We used the upper 
and lower limit of the 95% confidence interval of relative risk 
as input variables. It showed wide ranges of variation among 
older women, but the range converged for younger women. 
For women under age 40, there was little change with variation 
in relative risks. So, we thought that the conclusion of this study 
regarding women under the age of 40 is reliable.
We did not count pulmonary embolism as a life-threatening 
effect. Until now, there has been no data on pulmonary embo-
lism incidence in Korea. There is some hospital based data, 
none from the general population. The incidence of pulmo-
nary embolism in Korea is much lower than in the U.S. popu-
lation [10]. Therefore, we assumed that pulmonary embolism 
had little effect on the risk of tamoxifen.
Gail et al. [2] divided the effects of tamoxifen into three cat-
egories: life-threatening events, severe events and other events. 
Invasive breast cancer, hip fracture, endometrial cancer, stroke 
and pulmonary embolism were included in life-threatening 
events. They assumed that life-threatening events had the same 
magnitude of effect on the risk-benefit index. Strictly speaking, 
each event has different mortality and cost. Furthermore the 
magnitude of each event is subjective and each woman has dif-
ferent concerns regarding the same event. As they mentioned 
[2], no standard index would be particularly appropriate. How-
ever, they found the benefit of tamoxifen was insensitive to the 
particular weights used. In particular, breast cancer and endo-
metrial cancer had similar survival rates. So we thought that it 
was appropriate to use a risk-benefit index of the same magni-
tude.
Korean women had much higher risk of ischemic stroke 
than women in the U.S. The risk of stoke increased with age. 
Therefore, older Korean women had more risk than benefit 
from tamoxifen chemoprevention. Although this study had 
some drawbacks, we found that Korean women under age 40 
had more benefit than risk from tamoxifen chemoprevention. 
Tamoxifen chemoprevention should be limited to Korean 
women younger than age 40.
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